Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice

Polycystic ovary syndrome represents 80% of anovulatory infertility cases. Treatment initially includes preconception guidelines, such as lifestyle changes (weight loss), folic acid therapy to prevent the risk of fetal neural tube defects and halting the consumption of tobacco and alcohol. The first-line pharmacological treatment for inducing ovulation consists of a clomiphene citrate treatment for timed intercourse. The second-line pharmacological treatment includes the administration of exogenous gonadotropins or laparoscopic ovarian surgery (ovarian drilling). Ovulation induction using clomiphene citrate or gonadotropins is effective with cumulative live birth rates of approximately 70%. Ovarian drilling should be performed when laparoscopy is indicated; this procedure is typically effective in approximately 50% of cases. Finally, a high-complexity reproduction treatment (in vitro fertilization or intracytoplasmic sperm injection) is the third-line treatment and is recommended when the previous interventions fail. This option is also the first choice in cases of bilateral tubal occlusion or semen alterations that impair the occurrence of natural pregnancy. Evidence for the routine use of metformin in infertility treatment of anovulatory women with polycystic ovary syndrome is not available. Aromatase inhibitors are promising and longer term studies are necessary to prove their safety

Metabolic abnormalities in polycystic ovary syndrome women: obese and non obese

OBJETIVO: Comparar as características metabólicas de mulheres jovens do sudeste brasileiro, obesas e não obesas com síndrome dos ovários policísticos (SOP). MÉTODOS: Estudo transversal que incluiu 218 mulheres de idade reprodutiva com diagnóstico de SOP - 90 mulheres não obesas (IMC entre 18,5 e 29,9 kg/m²) e 128 pacientes obesas (IMC &gt;30 kg/m²), selecionadas no momento do diagnóstico. Foram comparadas as frequências de resistência insulínica (RI), intolerância à glicose (IG), síndrome metabólica (MetS) e diabetes mellitus tipo 2 (DM2) e os valores médios de colesterol total (CT), triglicérides (TG), lipoproteínas de alta (LDL) e baixa densidade (HDL), entre as pacientes obesas e não obesas com SOP. Foram comparadas também as características clínicas e hormonais (hormônio folículo estimulante, luteinizante, prolactina, hormônio tireoestimulante, testosterona total, sulfato de dehidroepiandrostenediona e 17-hidroxiprogesterona) nos dois grupos. A análise estatística foi realizada com o auxílio do software SAS 9.0. Para análise das variáveis com distribuição normal, utilizou-se o teste t de Student não pareado; na ausência desta característica, o teste utilizado foi Mann-Whitney bicaudal. Para as variáveis qualitativas utilizou-se o teste Exato de Fisher. Em todas as análises, foi considerado o nível de significância de 5% (p<0,05). RESULTADOS: As frequências de RI, IG e MetS foram significativamente mais elevadas em pacientes com SOP obesas do que não obesas (66,7, 29,9 e 63% versus 24,7, 12,2 e 16.4%, respectivamente). As pacientes obesas apresentaram maiores níveis de CT e TG (189,8±35.8 mg/dL e 145.4±71.1 mg/dL, respectivamente) do que as não obesas (172,1±38.4 mg/dL e 99,3±54 mg/dL, respectivamente). Ambos os grupos apresentaram níveis médios de HDL abaixo de 50 mg/dL. CONCLUSÕES: Mulheres obesas jovens com SOP apresentam maior frequência de RI, IG e SM do que as não obesas. Todavia, a ocorrência dos distúrbios metabólicos é elevada também na pacientes não obesas, sugerindo que a presença da síndrome favoreça o desenvolvimento de comorbidades metabólicas, com potenciais repercussões a médio e longo prazos.PURPOSE: To compare the metabolic characteristics of obese and non-obese young women with polycystic ovary syndrome (POS) from the Brazilian Southeast. METHODS: This was a cross-sectional study conducted on 218 women of reproductive age with a diagnosis of POS - 90 non-obese women (BMI between 18.5 and 29.9 kg/m²), and 128 obese patients (BMI &gt;30 kg/m²) selected at the time of diagnosis. The frequency of insulin resistance (IR), glucose intolerance (GI), metabolic syndrome (MetS) and type 2 diabetes mellitus (DM2) and mean values of total cholesterol (TC), triglycerides (TG), high-density (HDL) and low-density lipoproteins (LDL), were compared between obese and non-obese patients with POS. The two groups were also compared in terms of clinical and hormonal characteristics (follicle stimulating hormone, prolactin, thyroid stimulating hormone, total testosterone, dihydroepiandrostenedione sulfate, and 17-hydroxyprogesterone). Statistical analysis was performed using the SAS 9.0 software. Quantitative variables were compared by the Student´s t-test (data with normal distribution) or by the Mann-Whitney test (non-parametric distribution). Qualitative variables were compared by the Fisher test. The level of significance was set at 5% (p<0.05) in all analyses. RESULTS: The frequency of IR, GI and MetS was significantly higher in obese than non-obese patients with POS (66.7, 29.9, and 63% versus 24.7, 12.2, and 16.4%, respectively). Obese patients had higher TC and TG levels (189.8±35.8 mg/dL and 145.4±71.1 mg/dL, respectively) than non-obese patients (172.1±38.4 mg/dL and 99.3±54 mg/dL, respectively). Both groups had mean HDL levels below 50 mg/dL. CONCLUSIONS: Young obese women with POS have a higher frequency of IR, GI and MS than non-obese. However, the occurrence of metabolic disorders is elevated also in the non-obese patients, suggesting that the presence of the syndrome may favor the development of metabolic comorbidities with potential medium- and long-term repercussions

Which Factors Determine Spatial Segregation in the South American Opossums (Didelphis aurita and D. albiventris)? An Ecological Niche Modelling and Geometric Morphometrics Approach

Didelphis albiventris and D. aurita are Neotropical marsupials that share a unique evolutionary history and both are largely distributed throughout South America, being primarily allopatric throughout their ranges. In the Araucaria moist forest of Southern Brazil these species are sympatric and they might potentially compete having similar ecology. For this reason, they are ideal biological models to address questions about ecological character displacement and how closely related species might share their geographic space. Little is known about how two morphologically similar species of marsupials may affect each other through competition, if by competitive exclusion and competitive release. We combined ecological niche modeling and geometric morphometrics to explore the possible effects of competition on their distributional ranges and skull morphology. Ecological niche modeling was used to predict their potential distribution and this method enabled us to identify a case of biotic exclusion where the habit generalist D. albiventris is excluded by the presence of the specialist D. aurita. The morphometric analyses show that a degree of shape discrimination occurs between the species, strengthened by allometric differences, which possibly allowed them to occupy marginally different feeding niches supplemented by behavioral shift in contact areas. Overlap in skull morphology is shown between sympatric and allopatric specimens and a significant, but weak, shift in shape occurs only in D. aurita in sympatric areas. This could be a residual evidence of a higher past competition between both species, when contact zones were possibly larger than today. Therefore, the specialist D. aurita acts a biotic barrier to D. albiventris when niche diversity is not available for coexistence. On the other hand, when there is niche diversification (e.g. habitat mosaic), both species are capable to coexist with a minimal competitive effect on the morphology of D. aurita

Birth weight and Polycystic Ovary Syndrome: an additional association within fetal reprogramming?

Introdução:A história natural da Síndrome dos Ovários Policísticos (SOP) tem início durante a fase do crescimento fetal, que é umperíodo em que ocorre a diferenciação e a maturação funcional dos órgãos e tecidos. Quando surgem condições adversas durante a vida fetal, existe predomínio do processo catabólico, que promove a restriçãode crescimento intra-útero e o nascimento de recém-nascidos (RN) pequenos para a idade gestacional (PIG). Durante esta fase de hipoxemia fetal crônica, surgem alterações na expressão gênica de proteínas nucleares (reprogramação fetal) que poderão codificar manifestações fenotípicas na vida adulta, a depender das células que foram acometidas. Este processo, associado à predisposição genética e aos fatores ambientais, pode favorecer o surgimento da SOP. Objetivo:Avaliar se os RN de termo PIG (femininos) têm maior prevalência de SOP na idade adulta quando comparados aos RN Adequados para Idade Gestacional (AIG) na população da coorte de indivíduos nascidos em Ribeirão Preto durante o período de 31.05.1978 e 01.06.1979. Casuística e Métodos:Foram convocadas 440 mulheres de novembro/2007 à outubro/2008 para avaliação de repercussões reprodutivase metabólicas no menacme. Deste total, concordaram em participar da pesquisa 355 pacientes (268 AIG e 87 PIG), sendo que 138 AIGs e 37 PIGs foram excluídas devido ao uso de anticoncepcional hormonal (97) e pela presença de gestação ou amamentação (78). Todas as mulheres foram submetidas à anamnese (com avaliação da idade, das características do ciclo menstrual, dos sinais/sintomas do hiperandrogenismo, do peso, da altura e do índice de massa corpórea). Realizamos a dosagem hormonal (FSH, LH, prolactina, testosterona, DHEAS, 17-OH progesterona, insulina), a avaliação bioquímica (lipidograma, glicemia e teste de tolerância oral com 75 gramas de glicose), a SHBG e a ultra-sonografia pélvica para definição do diagnóstico de SOP. Também avaliamos o índice de androgênios livres (FAI),a resistência insulínica (RI) (através do HOMA) e a prevalência da síndrome metabólica (SMET). A coleta foi realizada entre o terceiro e o quinto dia do ciclo menstrual, após jejum de 12 horas. Resultados:a prevalência de SOP foi mais elevada no grupo PIG (32%) do que em mulheres do grupo AIG (13,8%), com risco relativo de 2,02 (IC95%: 1,27 - 3,21, p=0,0097) . Em relação aos critérios de SOP,a irregularidade menstrual (PIG: 51% vs AIG: 25,4%, p=0,0012) e o hiperandrogenismo (PIG: 41,2% vs AIG:22,3%, p=0,01) foram mais elevados nas pacientes PIG. Já a ultrassonografia, os exames bioquímicos, o FAI, e a avaliação hormonal não apresentaram diferenças significativas entre os grupos. Também não houve diferenças entre os grupos em relação às prevalências de SMET e RI. Conclusão: Mulheres PIG ao nascimento representam um grupo de risco para o desenvolvimento da SOP durante o menacme. Estudos de seguimento destas mulheres devem ser realizados para avaliar a relação do pesoao nascer com a prevalência de doenças cardiovasculares e metabólicas ao longo da vida.Introduction:The natural history of Polycystic Ovary Syndrome (POS) starts during fetal growth, a period during which the differentiation and functional maturation of organs and tissues occurs. When adverse conditions arise during fetal life there is a predominance of the catabolic process, which promotes intrauterine growth restriction and the birth of small for gestational age (SGA) newborns (NB). During this phase of chronic fetal hypoxemia, changes in the gene expression of nuclearproteins arise (fetal reprogramming) that might code for phenotypic manifestations during adult life depending on the affected cells. This process, together with genetic predisposition and environmental factors, may favor the onset of POS. Objective:To determine whether term female SGA NB have a higher prevalence of POS during adult age compared to women adequate for gestational age (AGA) at birth in the population of the cohort of individuals born in Ribeirão Preto during the period from 31.05.1978 to 01.06.1979. Cases and Methods:From November 2007 to October 2008, 440 women have been convoked for the assessment of reproductive and metabolic repercussions during menacme. Among them, 355 appeared (268 AGA and 87 SGA), with 137 AGAs and 38 SGAs being excluded from the study due to the use of a hormonal contraceptive (98) and to the presence of pregnancy or breast-feeding (77). The medical history of all women was taken, including age, characteristics of the menstrual cycle and of signs and symptoms of hyperandrogenism, height, and body mass index. We performed hormone determination (FSH, LH, prolactin, testosterone, DHEAS, 17-OH progesterone), biochemical evaluation (lipid profile, glycemia and 75 g oral glucose tolerance test), and pelvic ultrasound for the definition of the diagnosis of POS. Blood was collected between the third and fourth day ofthe menstrual cycle after a 12 hour fast. Results:The prevalence of POS was higher in the SGA group (32%) than in the AGA group (13.8%), with relative risk of 2,02 (IC 95%: 1,27- 3,21, p=0,0097). Regarding the criteria for a diagnosis of POS, chronic anovulation (SGA:51% vs AGA: 25,4%, p = 0.0012) and clinical hyperandrogenism (SGA: 41.2% vs AGA: 22.3%, p = 0.01) were more elevated in SGA patients. In contrast, ulrasonography and the biochemical and hormonal exams did not show significant differences between groups. Conclusion:Women who were SGA at birth represent a risk group for the development of POS during menacme. Following studies this women should be performed to assess the relation to birth weight with the prevalence of cardiovascular and metabolic diseases during of life

Birth weight and Polycystic Ovary Syndrome: an additional association within fetal reprogramming?

Introdução:A história natural da Síndrome dos Ovários Policísticos (SOP) tem início durante a fase do crescimento fetal, que é umperíodo em que ocorre a diferenciação e a maturação funcional dos órgãos e tecidos. Quando surgem condições adversas durante a vida fetal, existe predomínio do processo catabólico, que promove a restriçãode crescimento intra-útero e o nascimento de recém-nascidos (RN) pequenos para a idade gestacional (PIG). Durante esta fase de hipoxemia fetal crônica, surgem alterações na expressão gênica de proteínas nucleares (reprogramação fetal) que poderão codificar manifestações fenotípicas na vida adulta, a depender das células que foram acometidas. Este processo, associado à predisposição genética e aos fatores ambientais, pode favorecer o surgimento da SOP. Objetivo:Avaliar se os RN de termo PIG (femininos) têm maior prevalência de SOP na idade adulta quando comparados aos RN Adequados para Idade Gestacional (AIG) na população da coorte de indivíduos nascidos em Ribeirão Preto durante o período de 31.05.1978 e 01.06.1979. Casuística e Métodos:Foram convocadas 440 mulheres de novembro/2007 à outubro/2008 para avaliação de repercussões reprodutivase metabólicas no menacme. Deste total, concordaram em participar da pesquisa 355 pacientes (268 AIG e 87 PIG), sendo que 138 AIGs e 37 PIGs foram excluídas devido ao uso de anticoncepcional hormonal (97) e pela presença de gestação ou amamentação (78). Todas as mulheres foram submetidas à anamnese (com avaliação da idade, das características do ciclo menstrual, dos sinais/sintomas do hiperandrogenismo, do peso, da altura e do índice de massa corpórea). Realizamos a dosagem hormonal (FSH, LH, prolactina, testosterona, DHEAS, 17-OH progesterona, insulina), a avaliação bioquímica (lipidograma, glicemia e teste de tolerância oral com 75 gramas de glicose), a SHBG e a ultra-sonografia pélvica para definição do diagnóstico de SOP. Também avaliamos o índice de androgênios livres (FAI),a resistência insulínica (RI) (através do HOMA) e a prevalência da síndrome metabólica (SMET). A coleta foi realizada entre o terceiro e o quinto dia do ciclo menstrual, após jejum de 12 horas. Resultados:a prevalência de SOP foi mais elevada no grupo PIG (32%) do que em mulheres do grupo AIG (13,8%), com risco relativo de 2,02 (IC95%: 1,27 - 3,21, p=0,0097) . Em relação aos critérios de SOP,a irregularidade menstrual (PIG: 51% vs AIG: 25,4%, p=0,0012) e o hiperandrogenismo (PIG: 41,2% vs AIG:22,3%, p=0,01) foram mais elevados nas pacientes PIG. Já a ultrassonografia, os exames bioquímicos, o FAI, e a avaliação hormonal não apresentaram diferenças significativas entre os grupos. Também não houve diferenças entre os grupos em relação às prevalências de SMET e RI. Conclusão: Mulheres PIG ao nascimento representam um grupo de risco para o desenvolvimento da SOP durante o menacme. Estudos de seguimento destas mulheres devem ser realizados para avaliar a relação do pesoao nascer com a prevalência de doenças cardiovasculares e metabólicas ao longo da vida.Introduction:The natural history of Polycystic Ovary Syndrome (POS) starts during fetal growth, a period during which the differentiation and functional maturation of organs and tissues occurs. When adverse conditions arise during fetal life there is a predominance of the catabolic process, which promotes intrauterine growth restriction and the birth of small for gestational age (SGA) newborns (NB). During this phase of chronic fetal hypoxemia, changes in the gene expression of nuclearproteins arise (fetal reprogramming) that might code for phenotypic manifestations during adult life depending on the affected cells. This process, together with genetic predisposition and environmental factors, may favor the onset of POS. Objective:To determine whether term female SGA NB have a higher prevalence of POS during adult age compared to women adequate for gestational age (AGA) at birth in the population of the cohort of individuals born in Ribeirão Preto during the period from 31.05.1978 to 01.06.1979. Cases and Methods:From November 2007 to October 2008, 440 women have been convoked for the assessment of reproductive and metabolic repercussions during menacme. Among them, 355 appeared (268 AGA and 87 SGA), with 137 AGAs and 38 SGAs being excluded from the study due to the use of a hormonal contraceptive (98) and to the presence of pregnancy or breast-feeding (77). The medical history of all women was taken, including age, characteristics of the menstrual cycle and of signs and symptoms of hyperandrogenism, height, and body mass index. We performed hormone determination (FSH, LH, prolactin, testosterone, DHEAS, 17-OH progesterone), biochemical evaluation (lipid profile, glycemia and 75 g oral glucose tolerance test), and pelvic ultrasound for the definition of the diagnosis of POS. Blood was collected between the third and fourth day ofthe menstrual cycle after a 12 hour fast. Results:The prevalence of POS was higher in the SGA group (32%) than in the AGA group (13.8%), with relative risk of 2,02 (IC 95%: 1,27- 3,21, p=0,0097). Regarding the criteria for a diagnosis of POS, chronic anovulation (SGA:51% vs AGA: 25,4%, p = 0.0012) and clinical hyperandrogenism (SGA: 41.2% vs AGA: 22.3%, p = 0.01) were more elevated in SGA patients. In contrast, ulrasonography and the biochemical and hormonal exams did not show significant differences between groups. Conclusion:Women who were SGA at birth represent a risk group for the development of POS during menacme. Following studies this women should be performed to assess the relation to birth weight with the prevalence of cardiovascular and metabolic diseases during of life

Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice

Polycystic ovary syndrome represents 80% of anovulatory infertility cases. Treatment initially includes preconception guidelines, such as lifestyle changes (weight loss), folic acid therapy to prevent the risk of fetal neural tube defects and halting the consumption of tobacco and alcohol. The first-line pharmacological treatment for inducing ovulation consists of a clomiphene citrate treatment for timed intercourse. The second-line pharmacological treatment includes the administration of exogenous gonadotropins or laparoscopic ovarian surgery (ovarian drilling). Ovulation induction using clomiphene citrate or gonadotropins is effective with cumulative live birth rates of approximately 70%. Ovarian drilling should be performed when laparoscopy is indicated; this procedure is typically effective in approximately 50% of cases. Finally, a high-complexity reproduction treatment (in vitro fertilization or intracytoplasmic sperm injection) is the third-line treatment and is recommended when the previous interventions fail. This option is also the first choice in cases of bilateral tubal occlusion or semen alterations that impair the occurrence of natural pregnancy. Evidence for the routine use of metformin in infertility treatment of anovulatory women with polycystic ovary syndrome is not available. Aromatase inhibitors are promising and longer term studies are necessary to prove their safety

Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice

Polycystic ovary syndrome represents 80% of anovulatory infertility cases. Treatment initially includes preconception guidelines, such as lifestyle changes (weight loss), folic acid therapy to prevent the risk of fetal neural tube defects and halting the consumption of tobacco and alcohol. The first-line pharmacological treatment for inducing ovulation consists of a clomiphene citrate treatment for timed intercourse. The second-line pharmacological treatment includes the administration of exogenous gonadotropins or laparoscopic ovarian surgery (ovarian drilling). Ovulation induction using clomiphene citrate or gonadotropins is effective with cumulative live birth rates of approximately 70%. Ovarian drilling should be performed when laparoscopy is indicated; this procedure is typically effective in approximately 50% of cases. Finally, a high-complexity reproduction treatment (in vitro fertilization or intracytoplasmic sperm injection) is the third-line treatment and is recommended when the previous interventions fail. This option is also the first choice in cases of bilateral tubal occlusion or semen alterations that impair the occurrence of natural pregnancy. Evidence for the routine use of metformin in infertility treatment of anovulatory women with polycystic ovary syndrome is not available. Aromatase inhibitors are promising and longer term studies are necessary to prove their safety